OSR Health, Inc.
BioSniper AI · OSRH
OSR Health, Inc. (OSRH) is a biopharmaceutical company focused on developing therapies for osteoarthritis and other diseases, with a lead candidate oxysophoridine (OSR) and a major licensing agreement for VXM01.
Key risk: Preclinical stage only
Spotter reads the filings and answers with citations.
BioSniper Score
Based on 4 of 6 signals
Tracking 5 pipeline candidates for OSR Health, Inc. · Updated within the last hour.
OSR Health, Inc. (OSRH) is a biopharmaceutical company focused on developing therapies for osteoarthritis and other diseases, with a lead candidate oxysophoridine (OSR) and a major licensing agreement for VXM01.
- OSR Holdings entered a definitive global exclusive license agreement with BCM Europe AG for VXM01, with potential payments up to $815 million [news · 2026-04-29].
- Preclinical studies show oxysophoridine (OSR) protects chondrocytes from inflammation-induced impairment and alleviates osteoarthritis in mouse models [pubmed · 2026-02-03].
- Osteoarthritis is a prevalent joint disease with no cure, affecting ~10% of men and 18% of women over 60 globally [pubmed · 2026-02-03].
- A research report from December 2025 reaffirmed a Buy-Emerging rating and $10.00 price target for OSRH, citing the licensing agreement [news · 2025-12-04].
What works
- OSR has demonstrated anti-inflammatory and antioxidant effects in preclinical osteoarthritis models, reducing markers like IL-6, TNF-α, and MMP13 [pubmed · 2026-02-03].
- The global exclusive license agreement for VXM01 with BCM Europe AG provides a potential pathway for development and commercialization, with up to $815 million in milestone payments [news · 2026-04-29].
What to weigh
- OSR is still in preclinical stages for osteoarthritis, with no clinical trial data yet available for human efficacy or safety [pubmed · 2026-02-03].
- The company has a low stock price ($0.63 as of December 2025) and the licensing agreement is non-binding initially, with significant execution risk [news · 2025-12-04].
- Osteoarthritis has no cure, and current treatments focus only on symptom relief, indicating a challenging development path [pubmed · 2026-02-03].
From the filings
Quoted directly from source documents.
Oxysophoridine (OSR) protects chondrocytes from inflammation-induced impairment in preclinical models.
“Collectively, OSR protects chondrocytes from inflammation‑induced impairment.”
PubMed · February 3, 2026
Osteoarthritis prevalence is high in the aging population, with no cure.
“World Health Organization (WHO) estimates indicate that among individuals older than 60 years, osteoarthritis prevalence reaches approximately 10% in men and 18% in women.”
PubMed · February 3, 2026
Risks & what to watch (3)›
Key risks
- Preclinical stage only — OSR for osteoarthritis is in preclinical studies; no human clinical data available [pubmed · 2026-02-03].
- Low stock price and market cap — Stock closed at $0.63 in December 2025, indicating low market confidence [news · 2025-12-04].
- Licensing agreement execution risk — The $815 million deal is non-binding initially and subject to development milestones [news · 2025-12-04].
What to watch
- Initiation of clinical trials for oxysophoridine (OSR) in osteoarthritis [pubmed · 2026-02-03].
- Progress and milestones under the VXM01 license agreement with BCM Europe AG [news · 2026-04-29].
- Financial updates, including cash position and net loss, from future SEC filings.
Sources: News · PubMed · Generated July 14, 2026 · How we verify sources →
Unlock the full OSR Health, Inc. dossier
Sign in free to see catalysts, full pipeline, financials, FDA decisions, news, and run live AI deep-dives.
Free account includes:
- Full pipeline, catalysts, financials & FDA decisions for OSR Health, Inc.
- 200 free AI credits / month to run live Spotter deep-dives
- Watchlist, news alerts & the biotech event calendar
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
5.9 months
OCF -$1M
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for OSR Health, Inc.?
OSR Health, Inc. (OSRH) is a biopharmaceutical company focused on developing therapies for osteoarthritis and other diseases, with a lead candidate oxysophoridine (OSR) and a major licensing agreement for VXM01.
What is OSR Health, Inc.'s lead drug candidate?
OSR Health, Inc.'s most advanced tracked candidate is vxm01 (Phase 2) for glioblastoma.
Who is the CEO of OSR Health, Inc.?
Mr. Kuk Hyoun Hwang is the chief executive officer of OSR Health, Inc. (OSRH).
Where is OSR Health, Inc. headquartered?
OSR Health, Inc. (OSRH) is headquartered in Bellevue, WA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on OSR Health, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.